Mostrar el registro sencillo del ítem
dc.contributor.author | Montoya, Alonso | |
dc.contributor.author | Quail, Deborah | |
dc.contributor.author | Anand, Ernie | |
dc.contributor.author | Cardo-Jalon, Esther | |
dc.contributor.author | Alda, Jose A | |
dc.contributor.author | Escobar, Rodrigo | |
dc.date.accessioned | 2024-07-03T11:01:11Z | |
dc.date.available | 2024-07-03T11:01:11Z | |
dc.date.issued | 2014 | |
dc.identifier.citation | Montoya Alonso, Quail Deborah, Anand Ernie, Cardo Esther, Alda Jose A, Escobar Rodrigo. Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis.. Atten Defic Hyperact Disord. 2014;6(1):25-34. Epub 2013 Oct 20. | en |
dc.identifier.issn | 1866-6647 | |
dc.identifier.other | http://hdl.handle.net/20.500.13003/17105 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19942 | |
dc.description.abstract | The objective of this study is to identify prognostic factors of treatment response to atomoxetine in improvement of health-related quality of life (HR-QoL), measured by the Child Health and Illness Profile-Child Edition Parent Report Form (CHIP-CE PRF) Achievement and Risk Avoidance domains, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Pooled data from 3 placebo-controlled trials and separate data from 3 open-label trials of atomoxetine in children and adolescents with ADHD were analyzed using logistic regression methods. Based on baseline impairment in the Achievement and/or Risk Avoidance domains (CHIP-CE PRF < 40 points), 2 subsamples of subjects were included. Treatment outcome was categorized as <5 points or ?5 points increase in the CHIP-CE PRF Achievement and Risk Avoidance domains. Data of 190 and 183 subjects from the pooled sample, and 422 and 355 subjects from the open-label trials were included in the analysis of Achievement and Risk Avoidance domains. Baseline CHIP-CE subdomain scores proved to be the most robust prognostic factors for treatment outcome in both domains, based on data from the pooled sample of double-blind studies and from the individual open-label studies (odds ratios [OR] 0.74-1.56, p < 0.05; OR < 1, indicating a worse baseline score associated with worse odds of responding). Initial treatment response (?25 % reduction in ADHD Rating Scale scores in the first 4-6 weeks) was another robust prognostic factor, based on data from the open-label studies (OR 2.99-6.19, p < 0.05). Baseline impairment in HR-QoL and initial treatment response can be early prognostic factors of atomoxetine treatment outcome in HR-QoL in children and adolescents with ADHD. | en |
dc.language.iso | eng | en |
dc.rights.uri | https://creativecommons.org/licenses/by/3.0/ | * |
dc.subject.mesh | Child | * |
dc.subject.mesh | Clinical Trials as Topic | * |
dc.subject.mesh | Educational Status | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Risk Reduction Behavior | * |
dc.subject.mesh | Attention Deficit Disorder with Hyperactivity | * |
dc.subject.mesh | Double-Blind Method | * |
dc.subject.mesh | Prognosis | * |
dc.subject.mesh | Male | * |
dc.subject.mesh | Quality of Life | * |
dc.subject.mesh | Propylamines | * |
dc.subject.mesh | Female | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Logistic Models | * |
dc.title | Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis. | en |
dc.type | research article | en |
dc.rights.license | Attribution 3.0 Unported | * |
dc.identifier.pubmedID | 24142305 | es_ES |
dc.format.volume | 6 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 25-34 | es_ES |
dc.identifier.doi | 10.1007/s12402-013-0119-5 | |
dc.relation.publisherversion | https://dx.doi.org/10.1007/s12402-013-0119-5 | en |
dc.identifier.journal | Attention Deficit and Hyperactivity Disorders | es_ES |
dc.rights.accessRights | open access | en |
dc.subject.decs | Resultado del Tratamiento | * |
dc.subject.decs | Modelos Logísticos | * |
dc.subject.decs | Femenino | * |
dc.subject.decs | Conducta de Reducción del Riesgo | * |
dc.subject.decs | Masculino | * |
dc.subject.decs | Método Doble Ciego | * |
dc.subject.decs | Trastorno por Déficit de Atención con Hiperactividad | * |
dc.subject.decs | Propilaminas | * |
dc.subject.decs | Humanos | * |
dc.subject.decs | Calidad de Vida | * |
dc.subject.decs | Escolaridad | * |
dc.subject.decs | Pronóstico | * |
dc.subject.decs | Ensayos Clínicos como Asunto | * |
dc.subject.decs | Niño | * |
dc.identifier.scopus | 2-s2.0-84896893924 | |
dc.identifier.pui | L372493955 |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |